TY - JOUR
TI - Pricing of oral generic cancer medicines in 25 European countries;
findings and implications
AU - Godman, Brian
AU - Hill, Andrew
AU - Simoens, Professor Steven
AU - Kurdi,
AU - Amanj
AU - Gulbinovic, Jolanta
AU - Martin, Antony P.
AU - Timoney, Angela
AU - and Gotham, Dzintars
AU - Wale, Janet
AU - Bochenek, Tomasz
AU - Rothe,
AU - Celia C.
AU - Hoxha, Iris
AU - Malaj, Admir
AU - Hierlaender, Christian and
AU - Sauermann, Robert
AU - Hamelinck, Wouter
AU - Mitkova, Zornitsa and
AU - Petrova, Guenka
AU - Laius, Ott
AU - Sermet, Catherine
AU - Langer, Irene
AU - and Selke, Gisbert W.
AU - Yfantopoulos, John
AU - Joppi, Roberta and
AU - Jakupi, Arianit
AU - Poplavska, Elita
AU - Greiciute-Kuprijanov, Ieva and
AU - Bonanno, Patricia Vella
AU - Piepenbrink, J. F. (Hans)
AU - de Valk,
AU - Vincent
AU - Hagen, Carolin
AU - Ringerud, Anne Marthe
AU - Plisko, Robert
AU - and Wladysiuk, Magdalene
AU - Markovic-Pekovic, Vanda
AU - Grubisa, Natasa
AU - and Ponorac, Tatjana
AU - Mardare, Ileana
AU - Novakovic, Tanja and
AU - Parker, Mark
AU - Furst, Jurij
AU - Tomek, Dominik
AU - Cortadellas, Merce
AU - Obach
AU - Zara, Corinne
AU - Juhasz-Haverinen, Maria
AU - Skiold, Peter
AU - and McTaggart, Stuart
AU - Haycox, Alan
JO - GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL
PY - 2019
VL - 8
TODO - 2
SP - 49-70
PB - Pro Pharma Communications International
SN - null
TODO - 10.5639/gabij.2019.0802.007
TODO - Cancer; Europe; generic drug regulations; generics; health policy;
pricing
TODO - Introduction: There are appreciable concerns among European health
authorities with growing expenditure on cancer medicines and issues of
sustainability. The enhanced use of low-cost generics could help.
Aims: Consequently, there is a need to comprehensively document current
and future arrangements regarding the pricing of generic cancer
medicines across Europe, and whether these are indication specific, as
well as how this translates into actual prices to provide future
direction.
Methodology: Mixed-method approach with qualitative research among
senior health authority personnel and their advisers. Quantitative
research via health authority databases to ascertain current prices for
oral cancer medicines that had lost their patent and the influence of
population size and economics on prices.
Results: Twenty-five European countries participated. The research found
the following issues: (a) variable approaches to the pricing of generic
cancer medicines, which will continue; (b) no concerns with substitution
for oral generic cancer medicines; (c) substantial price reductions
versus originators for generic capecitabine (up to -93.1%), generic
imatinib (up to -97.8%) and generic temozolomide (up to -80.7%).
Prices for oncology medicines are not generally indication specific, and
are not affected by population size although influenced by pricing
approaches. There have also been price increases for some non-patented
cancer medicines following manufacturer changes although now
stabilizing.
Conclusion: The considerable price reductions seen for some generics
means health authorities should further encourage the use of generic
oncology medicines when they become available to fund increased volumes
and new valued cancer medicines. Countries are also starting to address
price increases for generics following changes in the manufacturer.
ER -